Novo Nordisk CEO Says Frehemgo and CagriSema to Launch in 2027
Novo Nordisk’s CEO said its haemophilia drug Frehemgo and obesity drug CagriSema are to launch in 2027.
Related stories
Magle Chemoswed Swings to Q3 Operating Loss of SEK 45 Million
M impact | EQUITY | Nov 04, 2026, 08:08 AM UTC
Demant Q3 Revenue Rises; Forecasts Growth; Resumes Buybacks
M impact | EQUITY | Nov 04, 2026, 08:01 AM UTC
SK Reit Q3 Net Profit Falls 19.6% Quarter on Quarter
SK Reit’s third-quarter 2026 net profit fell 19.6% from the previous quarter.
M impact | EQUITY | Nov 04, 2026, 08:01 AM UTC
SI-BONE Posts 14.5% Revenue Growth as Procedure Volume Rises 19.5%
M impact | EQUITY | Nov 04, 2026, 08:01 AM UTC
Hedera Group Reports Third-Quarter 2026 Results
Hedera Group AB reported third-quarter net sales, down year over year.
M impact | EQUITY | Nov 04, 2026, 08:01 AM UTC
LGI Homes Q3 Revenue Rises, Orders Fall; Credit Line Extended
M impact | EQUITY | Nov 04, 2026, 08:00 AM UTC